Synbio International, Inc. (OTC: SYIN) has taken a significant step toward generating revenue by entering into a strategic licensing, manufacturing, supply, and revenue sharing agreement with MD PHD Wellness, Inc. The deal grants Synbio exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations in the United States and Canada, according to a press release issued today.
The agreement covers MD PHD Wellness' flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio's Healing Force™ brand. It also establishes a framework for evaluating and commercializing additional wellness products over time. By securing access to existing proprietary products, Synbio avoids the time and cost associated with developing formulations from scratch, thereby accelerating its path to revenue generation.
Under the terms, MD PHD Wellness will manage product development, manufacturing, quality assurance, and supply chain, while Synbio will handle branding, marketing, sales, and distribution. After recovery of approved manufacturing and commercialization costs, profits will be shared between the parties.
Claudio Solitario, CEO of Synbio International, called the agreement a "transformational milestone" for the company. "Rather than building a nutraceutical business product by product, we have established a strategic partnership that combines MD PHD's product development and manufacturing expertise with Synbio's commercialization capabilities," he said. "It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time."
The move aligns with Synbio's broader strategy to build a diversified healthcare company. The company is also developing an AI-driven software that screens for mental health conditions using facial analysis. By generating revenue from nutraceutical sales, Synbio aims to support continued investment in its AI technologies. The global nutraceutical market is expanding rapidly, and Synbio is positioning itself to participate through a growing portfolio of scientifically developed products.
MD PHD Wellness was founded by Dr. Robert Lawrence, a physician and scientist with two Ph.D.s in Nuclear Physics and Biomedical Engineering. His career spans medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the proprietary formulations licensed to Synbio. He has served as a Research Physician and Senior Research Scientist at a prominent New York-based university, where he evaluated therapeutics, nutraceuticals, and emerging healthcare technologies.
The partnership underscores a growing trend of companies leveraging external expertise to quickly enter high-growth markets. For Synbio, this agreement provides a dual-track approach: near-term revenue from wellness products and long-term value from its AI-driven mental health technologies. As the company advances, it will focus on building brands, generating sales, and expanding market presence to maximize shareholder value.
